Navigation Links
BioMarin to Host Research and Development Day June 5th
Date:5/22/2008

NOVATO, Calif., May 22 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) will host a Research and Development Day for the financial community on Thursday, June 5, 2008 from 7:30 a.m. to 11:30 a.m. at the W New York Hotel in New York City. Members of BioMarin's senior management team will provide an overview of the company's product portfolio, new information about advancements in the research and development pipeline and other ongoing programs. Featured guests will include Dr. Barbara Burton, Professor of Pediatrics, Northwestern University Feinberg School of Medicine and Director, PKU Clinic at Children's Memorial Hospital.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Present at the Bank of America Healthcare Conference
2. BioMarin Announces First Quarter 2008 Financial Results
3. BioMarin to Present at the Morgan Stanley Healthcare Conference
4. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
5. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
6. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
7. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
8. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
9. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
10. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
11. BioMarin to Present at the BioCentury NewsMakers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... As the call for prior ... stakeholders, the discussion surrounding the topic will continue at WEDI 2017- Driving Solutions ... Angeles, Calif. Hosted by the Workgroup for Electronic Data Interchange (WEDI), the nation’s ...
(Date:4/25/2017)... R.I. , April 25, 2017 ... Inc. ("EpiVax") has licensed its novel immune-modulating technology to ... autoimmune disease and allergy. Tregitopes, pronounced ... in human immunoglobulin by EpiVax CEO Annie ... Similar to intravenous immunoglobulin G, an autoimmune disease ...
(Date:4/24/2017)... April 24, 2017  Dante Labs announced today the offer ... 850 (ca. $900). While American individuals have been able to ... Europeans can access WGS below EUR 1,000. The ... leveraging genetic information to make informed decisions about disease monitoring, ... ...
(Date:4/21/2017)... ... April 21, 2017 , ... The AMA is happy to ... graduates from across the nation. The scholarships are created through funds donated by model ... Scholarship criteria are set by the AMA Scholarship Committee, which is made up of ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):